nach oben

Endocrine

Erschienen in:

01.10.2011 | Review

Cross-talk and modulation of signaling between somatostatin and growth factor receptors

verfasst von: Ujendra Kumar

Erschienen in: Endocrine | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

The process of homo- and/or heterodimerization of G-protein coupled receptors (GPCRs) and receptor tyrosine kinase (RTK) families are crucial for implicating the fundamental properties of receptor proteins including receptor expression, trafficking, and desensitization as well as signal transduction. The members of GPCR and RTK family constitute largest cell surface receptor proteins and regulate physiological functions of cells in response to external and internal stimuli. Notably, GPCRs and RTKs play major role in regulation of several key cellular functions which are associated with several pathological conditions including cancer biology, neurodegenerative and cardiovascular diseases. The focus of this review is to highlight the recent findings on the possible cross-talk between somatostatin receptors (members of GPCR family) and growth factor receptors like epidermal growth factor receptors (members of RTK family). Furthermore, functional consequences of such an interaction in modulation of signaling pathways linked to pathological conditions specifically in cancer are discussed.

D. Fotiadis, Y. Liang, S. Filipek, D.A. Saperstein, A. Engel, K. Palczewski, Atomic-force microscopy: rhodopsin dimers in native disc membranes. Nature 421(6919), 127–128 (2003)PubMedCrossRef

M. Bouvier, N. Heveker, R. Jockers, S. Marullo, G. Milligan, BRET analysis of GPCR oligomerization: newer does not mean better. Nat. Methods 4(1), 3–4 (2007). author reply 4PubMedCrossRef

G. Milligan, G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol. 66(1), 1–7 (2004)PubMedCrossRef

U. Kumar, M. Grant, Somatostatin and somatostatin receptors. Results Probl. Cell Differ. 50, 137–184 (2010)PubMed

Y. Yarden, M.X. Sliwkowski, Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2(2), 127–137 (2001)PubMedCrossRef

J. Schlessinger, Cell signaling by receptor tyrosine kinases. Cell 103(2), 211–225 (2000)PubMedCrossRef

H. Daub, C. Wallasch, A. Lankenau, A. Herrlich, A. Ullrich, Signal characteristics of G protein-transactivated EGF receptor. EMBO J. 16(23), 7032–7044 (1997)PubMedCrossRef

L.M. Luttrell, Y. Daaka, R.J. Lefkowitz, Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr. Opin. Cell Biol. 11, 177–183 (1999)PubMedCrossRef

F.S. Lee, M.V. Chao, Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl. Acad. Sci. USA 98(6), 3555–3560 (2001)PubMedCrossRef

10.

K.L. Pierce, L.M. Luttrell, R.J. Lefkowitz, New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades. Oncogene 20(13), 1532–1539 (2001)PubMedCrossRef

11.

P.O. Hackel, E. Zwick, N. Prenzel, A. Ullrich, Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr. Opin. Cell Biol. 11(2), 184–189 (1999)PubMedCrossRef

12.

B. Hellman, A. Lernmark, Inhibition of the in vitro secretion of insulin by an extract of pancreatic alpha-1 cells. Endocrinology 84(6), 1484–1488 (1969)PubMedCrossRef

13.

L. Krulich, A.P. Dhariwal, S.M. McCann, Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 83(4), 783–790 (1968)PubMedCrossRef

14.

Y.C. Patel, S. Reichlin, Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat. Endocrinology 102(2), 523–530 (1978)PubMedCrossRef

15.

Y.C. Patel, Somatostatin and its receptor family. Front. Neuroendocrinol. 20(3), 157–198 (1999)PubMedCrossRef

16.

J. Epelbaum, P. Dournaud, M. Fodor, C. Viollet, The neurobiology of somatostatin. Crit. Rev. Neurobiol. 8(1–2), 25–44 (1994)PubMed

17.

Y.C. Patel, Molecular pharmacology of somatostatin receptor subtypes. J. Endocrinol. Invest. 20(6), 348–367 (1997)PubMed

18.

U. Kumar, D. Laird, C.B. Srikant, E. Escher, Y.C. Patel, Expression of the five somatostatin receptor (SSTR1–5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopy. Endocrinology 138(10), 4473–4476 (1997)PubMedCrossRef

19.

K.V. Sorensen, S.E. Christensen, A.P. Hansen, E. Pedersen, H. Orskov, Cerebrospinal fluid somatostatin inversely correlated with disease activity in multiple sclerosis. Lancet 1(8331), 988 (1983)PubMedCrossRef

20.

D. Hoyer, H. Lubbert, C. Bruns, Molecular pharmacology of somatostatin receptors. Naunyn Schmiedebergs Arch Pharmacol 350(5), 441–453 (1994)PubMedCrossRef

21.

A. Schonbrunn, H. Tashjian Jr., Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J. Biol. Chem. 253(18), 6473–6483 (1978)PubMed

22.

K.D. Pfleger, K.A. Eidne, Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells. Biochem. J. 385(Pt 3), 625–637 (2005)PubMed

23.

S. Bulenger, S. Marullo, M. Bouvier, Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol. Sci. 26(3), 131–137 (2005)PubMedCrossRef

24.

M. Duran-Prado, M.M. Malagon, F. Gracia-Navarro, J.P. Castano, Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Mol. Cell. Endocrinol. 286(1–2), 63–68 (2008)PubMedCrossRef

25.

J.M. Gripentrog, K.P. Kantele, A.J. Jesaitis, H.M. Miettinen, Experimental evidence for lack of homodimerization of the G protein-coupled human N-formyl peptide receptor. J. Immunol. 171(6), 3187–3193 (2003)PubMed

26.

B.H. Meyer, J.M. Segura, K.L. Martinez, R. Hovius, N. George, K. Johnsson, H. Vogel, FRET imaging reveals that functional neurokinin-1 receptors are monomeric and reside in membrane microdomains of live cells. Proc. Natl. Acad. Sci. USA 103(7), 2138–2143 (2006)PubMedCrossRef

27.

M. Grant, B. Collier, U. Kumar, Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J. Biol. Chem. 279(35), 36179–36183 (2004)PubMedCrossRef

28.

M. Pfeiffer, T. Koch, H. Schroder, M. Klutzny, S. Kirscht, H.J. Kreienkamp, V. Hollt, S. Schulz, Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J. Biol. Chem. 276(17), 14027–14036 (2001)PubMed

29.

M.A. Ayoub, C. Couturier, E. Lucas-Meunier, S. Angers, P. Fossier, M. Bouvier, R. Jockers, Monitoring of ligand-independent dimerization and ligand-induced conformational changes of melatonin receptors in living cells by bioluminescence resonance energy transfer. J. Biol. Chem. 277(24), 21522–21528 (2002)PubMedCrossRef

30.

M. Rocheville, D.C. Lange, U. Kumar, R. Sasi, R.C. Patel, Y.C. Patel, Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 275(11), 7862–7869 (2000)PubMedCrossRef

31.

M. Grant, R.C. Patel, U. Kumar, The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J. Biol. Chem. 279(37), 38636–38643 (2004)PubMedCrossRef

32.

M. Duran-Prado, C. Bucharles, B.J. Gonzalez, R. Vazquez-Martinez, A.J. Martinez-Fuentes, S. Garcia-Navarro, S.J. Rhodes, H. Vaudry, M.M. Malagon, J.P. Castano, Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization. Endocrinology 148(1), 411–421 (2007)PubMedCrossRef

33.

S.A. War, R.K. Somvanshi, U. Kumar, Somatostatin receptor-3 mediated intracellular signaling and apoptosis is regulated by its cytoplasmic terminal. Biochim. Biophys. Acta 1813(3), 390–402 (2011)PubMedCrossRef

34.

R.K. Somvanshi, S. Billova, G. Kharmate, P.S. Rajput, U. Kumar, C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell. Signal. 21(9), 1396–1414 (2009)PubMedCrossRef

35.

A. Baragli, H. Alturaihi, H.L. Watt, A. Abdallah, U. Kumar, Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell. Signal. 19(11), 2304–2316 (2007)PubMedCrossRef

36.

M. Grant, H. Alturaihi, P. Jaquet, B. Collier, U. Kumar, Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol. Endocrinol. 22(10), 2278–2292 (2008)PubMedCrossRef

37.

M. Pfeiffer, T. Koch, H. Schroder, M. Laugsch, V. Hollt, S. Schulz, Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J. Biol. Chem. 277(22), 19762–19772 (2002)PubMedCrossRef

38.

M. Rocheville, D.C. Lange, U. Kumar, S.C. Patel, R.C. Patel, Y.C. Patel, Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288(5463), 154–157 (2000)PubMedCrossRef

39.

R.K. Somvanshi, N. Chaudhari, X. Qiu, U. Kumar, Heterodimerization of beta2 adrenergic receptor and somatostatin receptor 5: implications in modulation of signaling pathway. J. Mol. Signal. 6, 9 (2011)

40.

R.K. Somvanshi, S.A. War, N. Chaudhari, X. Qiu, U. Kumar, Receptor specific crosstalk and modulation of signaling upon heterodimerization between beta1-adrenergic receptor and somatostatin receptor-5. Cell. Signal. 23(5), 794–811 (2011)PubMedCrossRef

41.

G. Kharmate, P.S. Rajput, H.L. Watt, R.K. Somvanshi, N. Chaudhari, X. Qiu, U. Kumar, Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signaling pathways. Endocrinology 152(3), 931–945 (2011)PubMedCrossRef

42.

G. Kharmate, P.S. Rajput, H.L. Watt, R.K. Somvanshi, N. Chaudhari, X. Qiu, U. Kumar, Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling. Biochim. Biophys. Acta 1813(6), 1172–1189 (2011)PubMedCrossRef

43.

H.L. Watt, G.D. Kharmate, U. Kumar, Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell. Signal. 21(3), 428–439 (2009)PubMedCrossRef

44.

M. Grant, U. Kumar, The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul. Pept. 159(1–3), 3–8 (2010)PubMedCrossRef

45.

R.C. Patel, U. Kumar, D.C. Lamb, J.S. Eid, M. Rocheville, M. Grant, A. Rani, T. Hazlett, S.C. Patel, E. Gratton, Y.C. Patel, Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc. Natl. Acad. Sci. USA 99(5), 3294–3299 (2002)PubMedCrossRef

46.

Y.C. Patel, M.T. Greenwood, A. Warszynska, R. Panetta, C.B. Srikant, All five cloned human somatostatin receptors (hSSTR1–5) are functionally coupled to adenylyl cyclase. Biochem. Biophys. Res. Commun. 198(2), 605–612 (1994)PubMedCrossRef

47.

M.A. Olayioye, R.M. Neve, H. Lane, N.E. Hynes, The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19(13), 3159–3167 (2000)PubMedCrossRef

48.

D.C. Lev, L.S. Kim, V. Melnikova, M. Ruiz, H.N. Ananthaswamy, J.E. Price, Dual blockade of EGFR and ERK1/2 phosphorylation potentiates growth inhibition of breast cancer cells. Br. J. Cancer 91(4), 795–802 (2004)PubMed

49.

S. Okubo, J. Kurebayashi, T. Otsuki, Y. Yamamoto, K. Tanaka, H. Sonoo, Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182, 780) in breast cancer cells. Br. J. Cancer 90(1), 236–244 (2004)PubMedCrossRef

50.

A. deFazio, Y.E. Chiew, R.L. Sini, P.W. Janes, R.L. Sutherland, Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int. J. Cancer 87(4), 487–498 (2000)PubMedCrossRef

51.

D.F. Stern, ErbBs in mammary development. Exp. Cell Res. 284(1), 89–98 (2003)PubMedCrossRef

52.

H.K. Gan, M. Lappas, D.X. Cao, A. Cvrljevdic, A.M. Scott, T.G. Johns, Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. J. Cell Mol. Med. 13(9B), 3993–4001 (2009)PubMedCrossRef

53.

D. Gerber, N. Sal-Man, Y. Shai, Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization. J. Biol. Chem. 279(20), 21177–21182 (2004)PubMedCrossRef

54.

A.W. Burgess, H.S. Cho, C. Eigenbrot, K.M. Ferguson, T.P. Garrett, D.J. Leahy, M.A. Lemmon, M.X. Sliwkowski, C.W. Ward, S. Yokoyama, An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12(3), 541–552 (2003)PubMedCrossRef

55.

T.P. Garrett, N.M. McKern, M. Lou, T.C. Elleman, T.E. Adams, G.O. Lovrecz, M. Kofler, R.N. Jorissen, E.C. Nice, A.W. Burgess, C.W. Ward, The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11(2), 495–505 (2003)PubMedCrossRef

56.

L.N. Klapper, M.H. Kirschbaum, M. Sela, Y. Yarden, Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77, 25–79 (2000)PubMedCrossRef

57.

K.L. Carraway 3rd, L.C. Cantley, A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78(1), 5–8 (1994)PubMedCrossRef

58.

J.L. Gilmore, D.J. Riese 2nd, secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. Oncol. Res. 14(11–12), 589–602 (2004)PubMed

59.

K.L. Carraway 3rd, S.P. Soltoff, A.J. Diamonti, L.C. Cantley, Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3. J. Biol. Chem. 270(13), 7111–7116 (1995)PubMedCrossRef

60.

B.D. Cohen, P.A. Kiener, J.M. Green, L. Foy, H.P. Fell, K. Zhang, The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J. Biol. Chem. 271(48), 30897–30903 (1996)PubMedCrossRef

61.

P.M. Guy, J.V. Platko, L.C. Cantley, R.A. Cerione, K.L. Carraway 3rd, Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 91(17), 8132–8136 (1994)PubMedCrossRef

62.

T. Holbro, R.R. Beerli, F. Maurer, M. Koziczak, C.F. Barbas 3rd, N.E. Hynes, The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100(15), 8933–8938 (2003)PubMedCrossRef

63.

R. Pinkas-Kramarski, M. Shelly, S. Glathe, B.J. Ratzkin, Y. Yarden, Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J. Biol. Chem. 271(32), 19029–19032 (1996)PubMedCrossRef

64.

K. Zhang, J. Sun, N. Liu, D. Wen, D. Chang, A. Thomason, S.K. Yoshinaga, Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271(7), 3884–3890 (1996)PubMedCrossRef

65.

J. Baulida, G. Carpenter, Heregulin degradation in the absence of rapid receptor-mediated internalization. Exp. Cell Res. 232(1), 167–172 (1997)PubMedCrossRef

66.

Z. Wang, L. Zhang, T.K. Yeung, X. Chen, Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol. Biol. Cell 10(5), 1621–1636 (1999)PubMed

67.

H. Waterman, I. Sabanai, B. Geiger, Y. Yarden, Alternative intracellular routing of ErbB receptors may determine signaling potency. J. Biol. Chem. 273(22), 13819–13827 (1998)PubMedCrossRef

68.

A.E. Lenferink, R. Pinkas-Kramarski, M.L. van de Poll, M.J. van Vugt, L.N. Klapper, E. Tzahar, H. Waterman, M. Sela, E.J. van Zoelen, Y. Yarden, Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 17(12), 3385–3397 (1998)PubMedCrossRef

69.

R. Zandi, A.B. Larsen, P. Andersen, M.T. Stockhausen, H.S. Poulsen, Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell. Signal. 19(10), 2013–2023 (2007)PubMedCrossRef

70.

E. Peles, R. Ben-Levy, E. Tzahar, N. Liu, D. Wen, Y. Yarden, Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 12(3), 961–971 (1993)PubMed

71.

G.D. Plowman, J.M. Green, J.M. Culouscou, G.W. Carlton, V.M. Rothwell, S. Buckley, Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 366(6454), 473–475 (1993)PubMedCrossRef

72.

M.X. Sliwkowski, G. Schaefer, R.W. Akita, J.A. Lofgren, V.D. Fitzpatrick, A. Nuijens, B.M. Fendly, R.A. Cerione, R.L. Vandlen, K.L. Carraway 3rd, Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269(20), 14661–14665 (1994)PubMed

73.

X. Qian, C.M. LeVea, J.K. Freeman, W.C. Dougall, M.I. Greene, Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc. Natl. Acad. Sci. USA 91(4), 1500–1504 (1994)PubMedCrossRef

74.

S. Gavi, D. Yin, E. Shumay, H.Y. Wang, C.C. Malbon, Insulin-like growth factor-I provokes functional antagonism and internalization of beta1-adrenergic receptors. Endocrinology 148(6), 2653–2662 (2007)PubMedCrossRef

75.

F.S. Lee, Novel crosstalk between G protein-coupled receptors and NMDA receptors. Exp. Neurol. 183(2), 269–272 (2003)PubMedCrossRef

76.

J.A. Garcia-Sainz, M.T. Romero-Avila, C. Medina Ldel, Dissecting how receptor tyrosine kinases modulate G protein-coupled receptor function. Eur. J. Pharmacol. 648(1–3), 1–5 (2010)PubMedCrossRef

77.

U. Kumar, S.I. Grigorakis, H.L. Watt, R. Sasi, L. Snell, P. Watson, S. Chaudhari, Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res. Treat. 92(2), 175–186 (2005)PubMedCrossRef

78.

H.L. Watt, U. Kumar, Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells. Cancer Cell. Int. 6, 5 (2006)PubMedCrossRef

79.

J. Held-Feindt, F. Forstreuter, T. Pufe, R. Mentlein, Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. Brain Res. Mol. Brain Res. 87(1), 12–21 (2001)PubMedCrossRef

80.

M.T. Lee, C. Liebow, A.R. Kamer, A.V. Schally, Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc. Natl. Acad. Sci. USA 88(5), 1656–1660 (1991)PubMedCrossRef

81.

S. Hart, O.M. Fischer, N. Prenzel, E. Zwick-Wallasch, M. Schneider, L. Hennighausen, A. Ullrich, GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. Biol. Chem. 386(9), 845–855 (2005)PubMedCrossRef

82.

E.J. Filardo, J.A. Quinn, K.I. Bland, A.R. Frackelton Jr., Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14(10), 1649–1660 (2000)PubMedCrossRef

83.

N. Prenzel, E. Zwick, H. Daub, M. Leserer, R. Abraham, C. Wallasch, A. Ullrich, EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402(6764), 884–888 (1999)PubMed

84.

H. Daub, F.U. Weiss, C. Wallash, A. Ullrich, Role of transactivation of the EGF receptor in signalling by G-protein coupled receptors. Nature 379, 557–560 (1996)PubMedCrossRef

85.

D. Darmoul, V. Gratio, H. Devaud, M. Laburthe, Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J. Biol. Chem. 279(20), 20927–20934 (2004)PubMedCrossRef

86.

H. Shankaran, H.S. Wiley, H. Resat, Modeling the effects of HER/ErbB1–3 coexpression on receptor dimerization and biological response. Biophys. J. 90(11), 3993–4009 (2006)PubMedCrossRef

87.

N.E. Willmarth, A. Baillo, M.L. Dziubinski, K. Wilson, D.J. Riese Ii, S.P. Ethier, Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell. Signal. 21(2), 212–219 (2009)PubMedCrossRef

88.

N. Moghal, P.W. Sternberg, Multiple positive and negative regulators of signaling by the EGF-receptor. Curr. Opin. Cell Biol. 11(2), 190–196 (1999)PubMedCrossRef

89.

W.J. Wu, S. Tu, R.A. Cerione, Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell 114(6), 715–725 (2003)PubMedCrossRef

90.

T. Fukazawa, S. Miyake, V. Band, H. Band, Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J. Biol. Chem. 271(24), 14554–14559 (1996)PubMedCrossRef

91.

T. Florio, S. Thellung, S. Arena, A. Corsaro, A. Bajetto, G. Schettini, P.J. Stork, Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J. Physiol. Paris 94(3–4), 239–250 (2000)PubMedCrossRef

92.

T. Florio, H. Yao, K.D. Carey, T.J. Dillon, P.J. Stork, Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol. Endocrinol. 13(1), 24–37 (1999)PubMedCrossRef

93.

H. Lahlou, N. Saint-Laurent, J.P. Esteve, A. Eychene, L. Pradayrol, S. Pyronnet, C. Susini, sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J. Biol. Chem. 278(41), 39356–39371 (2003)PubMedCrossRef

94.

A. Esparis-Ogando, E. Diaz-Rodriguez, J.C. Montero, L. Yuste, P. Crespo, A. Pandiella, Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol. Cell. Biol. 22(1), 270–285 (2002)PubMedCrossRef

95.

J.C. Montero, A. Ocana, M. Abad, M.J. Ortiz-Ruiz, A. Pandiella, A. Esparis-Ogando, Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS One 4(5), e5565 (2009)PubMedCrossRef

96.

N.E. Hynes, J.H. Dey, PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough. Cancer Cell 15(5), 353–355 (2009)PubMedCrossRef

97.

B.N. Rexer, R. Ghosh, C.L. Arteaga, Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clin. Cancer Res. 15(14), 4518–4520 (2009)PubMedCrossRef

98.

B.N. Rexer, J.A. Engelman, C.L. Arteaga, Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 8(1), 18–22 (2009)PubMedCrossRef

99.

K. Berns, H.M. Horlings, B.T. Hennessy, M. Madiredjo, E.M. Hijmans, K. Beelen, S.C. Linn, A.M. Gonzalez-Angulo, K. Stemke-Hale, M. Hauptmann, R.L. Beijersbergen, G.B. Mills, M.J. van de Vijver, R. Bernards, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4), 395–402 (2007)PubMedCrossRef

100.

C.B. Srikant, S.H. Shen, Octapeptide somatostatin analog SMS 201–995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 137(8), 3461–3468 (1996)PubMedCrossRef

101.

C. Susini, L. Buscail, Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 17(12), 1733–1742 (2006)PubMedCrossRef

102.

M.P. Sanderson, P.J. Dempsey, A.J. Dunbar, Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors 24(2), 121–136 (2006)PubMedCrossRef

Titel: Cross-talk and modulation of signaling between somatostatin and growth factor receptors
verfasst von: Ujendra Kumar
Publikationsdatum: 01.10.2011
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2011
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-011-9524-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Evaluation of bone markers in hypophosphatemic rickets/osteomalacia

Looking after silent coronary artery disease in diabetic patients. When and how?

Ghrelin reduces voltage-gated calcium currents in GH3 cells via cyclic GMP pathways

Evaluation of oxidative status in patients with hyperthyroidism

Gene expression profiling supports the role of Repin1 in the pathophysiology of metabolic syndrome